WORLD VACCINE CONGRESS EUROPE 2023


Associated tags: Congress, Safety, Pharmaceutical industry, NHP, Messenger, Tissue, Immunization, Combined, CEST, Biotechnology, Heart, UTR, MPH, MicroRNA, Liver, Therapy, Immunity, Cell, RNA, CTX

Combined Therapeutics CEO, Romain Micol, to Present at the World Vaccine Congress Europe 2023

Retrieved on: 
Wednesday, October 11, 2023
Congress, UTR, CTX, RNA, Cell, Immunity, Therapy, Liver, MicroRNA, MPH, Heart, Safety, Biotechnology, CEST, Combined, Immunization, Tissue, Messenger, NHP, Pharmaceutical industry, Vaccine

BOSTON, Oct. 11, 2023 /PRNewswire/ -- Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA vaccines and therapeutics with a novel modified-mRNA platform to treat and prevent infectious diseases and cancer, today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the World Vaccine Congress Europe 2023, taking place from October 17 to 19 in Barcelona, Spain.

Key Points: 
  • "We are elated to share our findings at the World Vaccine Congress Europe 2023 and to discuss our progress toward developing the next generation of mRNA vaccines," said Dr. Romain Micol, CEO of Combined Therapeutics.
  • "Our MOPCTx mRNA platform has demonstrated exceptional promise in preclinical studies, showcasing an enhanced biodistribution profile, improved organ protection, and no compromise in vaccine efficacy.
  • Its precision in targeting therapeutic protein expression while simultaneously safeguarding vital organs represents an important advancement in our field."
  • Proof of concept studies in non-human primates (NHPs) confirmed the efficacy of the MOPCTx platform in decreasing overall systemic vaccine antigen expression after intramuscular immunization.